Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06140303 · ClinicalTrials.gov registry record · Phase 3

SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)

A Phase 3 study of Diabetic Foot, sponsored by PolarityTE.

Active
Registry status
Phase 3
Development phase
100
Enrollment target
20
Study locations

NCT06140303: Active Phase 3 study of Diabetic Foot, sponsored by PolarityTE.

NCT06140303 is a Phase 3 study of Diabetic Foot that is active but no longer recruiting, run by PolarityTE. The registered enrollment target is 100 participants, below the 10,338-participant average among 30 other Diabetic Foot trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06140303, a Phase 3 study of Diabetic Foot, is active but no longer recruiting, sponsored by PolarityTE.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety and efficacy of SkinTE for treatment of Wagner grade 1 diabetic foot ulcers.

Primary Outcome

Wound closure is confirmed at two consecutive visits each two weeks apart

Conditions Studied

Interventions

  • OTHER Control
  • BIOLOGICAL SkinTE

Study Locations (20)

California

  • Center for Clinical Research - Castro Valley
  • Limb Preservation Platform, Inc. - Fresno
  • Angel City Research - Los Angeles
  • Clemente Clinical Research Inc. - Los Angeles
  • Center for Clinical Research - San Francisco
  • Clemente Clinical Research Inc. - Santa Ana
  • ILD Research - Vista

Florida

  • Las Mercedes Medical Research, Inc. - Hialeah
  • Doctors Research Network - Miami
  • DMI Research - Pinellas Park
  • Barry University Clinical Research - Tamarac

Ohio

  • LEIRT (Lower Extremity Institute for Research and Therapy) - Boardman
  • Cutting Edge Research LLC - Circleville
  • LEIRT (Lower Extremity Institute for Research and Therapy) - East Liverpool
  • Cutting Edge Research LLC - Grove City

New York

  • Northwell Health, Inc. - New Hyde Park
  • Mount Sinai West Hospital - New York

Arizona

  • Titan Clinical Research - Mesa

Maryland

  • FASMA - Hagerstown - Hagerstown

Nevada

  • Viable Research Management - Henderson

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-02-22
Est. Completion 2026-03-31
Phase Phase 3
PolarityTE

4 total trials

What the registry record for NCT06140303 still lists

NCT06140303 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 10,338-participant average among 30 other Diabetic Foot trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Diabetic Foot appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.

NCT06140303 names 20 study sites across 7 states, led by California, Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT06140303 about?

NCT06140303 is a clinical study titled "SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)". The purpose of this study is to assess the safety and efficacy of SkinTE for treatment of Wagner grade 1 diabetic foot ulcers.

What is the current status of trial NCT06140303?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2024-02-22. Estimated completion is 2026-03-31.

What conditions does trial NCT06140303 study?

This clinical trial studies the following conditions: Diabetic Foot.

What interventions are being tested in trial NCT06140303?

The interventions under investigation include: Control (OTHER), SkinTE (BIOLOGICAL).

Who is sponsoring clinical trial NCT06140303?

This trial is sponsored by PolarityTE, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06140303 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Maryland, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Foot

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06140303's enrollment target sits among peer trials

100 20th of 30 higher than 10 of 30 other Diabetic Foot trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Foot trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06140303, the US trial registry maintained by the National Library of Medicine. NCT06140303 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.